BIOFINITY (COMFILCON A)
CooperVision, Inc. · Decision date Sep 2, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-02 for PMA supplement P080011/S204, associated with BIOFINITY (COMFILCON A), a soft extended-wear contact lens (product code LPM, ophthalmic specialty), held by CooperVision, Inc. The supplement was filed as a 30-Day Notice with the reason recorded as a process change affecting manufacturer, sterilizer, packager or supplier.
The recorded statement covers introduction of a new Density Meter at the Juana Diaz, Puerto Rico facility. This is a supplement-level decision about that manufacturing change, not a new approval of the BIOFINITY lens system as a whole. The source record does not describe the meter's specifications, its role in production or release testing, or any supporting data, and no documents were included, so the technical basis for OK30 cannot be assessed from this entry.
FDA approval order statement
introduction of a new Density Meter at the Juana Diaz, Puerto Rico facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080011/S204
- Regulatory pathway
- PMA supplement
- Applicant
- CooperVision, Inc.
- Product code
- LPM
- Decision code
- OK30
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Applicant
- CooperVision, Inc.
- Product code
- LPM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P080011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P080011 · Original PMA
BIOFINITY (COMFILCON A)
P080011/S204 received
Application receipt date recorded by FDA.
P080011/S204 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P080011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BIOFINITY (COMFILCON A)P080011 | CooperVision, Inc. | PMA approval | Nov 19, 2008 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
| Bausch and Lomb, Inc., | PMA approval | Apr 30, 2018 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CooperVision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6101 Bollinger Canyon Rd., Suite 500, San Ramon, CA, 94583
Sources and methodology
- Original FDA record: P080011/S204
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


